Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
116.330USD
+3.180+2.81%
Close 09-16 16:00（ET）
9.64BMarket Cap
LossP/E TTM
Kymera Therapeutics Inc (KYMR) Stock Price Target & Forecast
Analyst Rating
Based on 23 analysts giving stock ratings to Kymera Therapeutics Inc in the past month.
Buy
9 Strong Buy
12 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
137.619USD+21.63%
KYMR Analyst Recommendation Trends
In the current month, KYMR has received 12 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the last month is 137.619.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
9
8
8
9
9
9
9
9
12
12
14
14
13
13
13
13
2
3
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
23
23
24
23
23
23
23
KYMR Analyst Rating for Peer Comparison
Updated: Sep 16, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, KYMR EPS is projected to reach -1.248 in FY2026Q3, following reported EPS of -0.623 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.80
-0.88
-0.71
-1.25
-1.26
Actual
-0.97
-0.71
-0.62
--
--
Surprise
-21.37%
+19.49%
+12.56%
--
--
FAQs
What is Kymera Therapeutics Inc's expected revenue for the next quarter?
Kymera Therapeutics Inc's expected revenue is 3.10M.
What is Kymera Therapeutics Inc's price target?
Analysts forecast that Kymera Therapeutics Inc's price target is USD 137.62, with the highest forecast at USD 180.00 and the lowest forecast at USD 111.00.
How have Kymera Therapeutics IncKYMR's recent earnings per share performed?
The market expectation was USD -0.62, while Kymera Therapeutics IncKYMR's earnings per share (EPS) for the previous quarter was USD -0.71. EPS for the next quarter is expected at USD -1.25.
What is the analyst rating for Kymera Therapeutics Inc?
Based on the ratings of Kymera Therapeutics Inc's stock from 23 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.